Journal of Cardiac Failure
Volume 15, Issue 3 , Pages 171-181 , April 2009

Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID Trial), a First-in-Human Phase 1/2 Clinical Trial

  • Brian E. Jaski, MD, FACC

      Affiliations

    • San Diego Cardiac Center, San Diego, California
    • Corresponding Author InformationReprint requests: Dr. Brian E. Jaski, San Diego Cardiac Center, 3131 Berger Avenue, San Diego, CA92123. Phone: (858) 244-6800; Fax: (858) 244-6909.
    • ,
  • Mariell L. Jessup, MD

      Affiliations

    • Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
    • ,
  • Donna M. Mancini, MD

      Affiliations

    • New York-Presbyterian Hospital/Columbia University Hospital, New York, New York
    • ,
  • Thomas P. Cappola, MD

      Affiliations

    • Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
    • ,
  • Daniel F. Pauly, MD, PhD

      Affiliations

    • Shands Hospital at the University of Florida, Gainesville, Florida
    • ,
  • Barry Greenberg, MD

      Affiliations

    • University of California at San Diego Medical Center, San Diego, California
    • ,
  • Kenneth Borow, MD

      Affiliations

    • Wayne, Pennsylvania
    • ,
  • Howard Dittrich, MD

      Affiliations

    • University of California at San Diego, San Diego, California
    • ,
  • Krisztina M. Zsebo, PhD

      Affiliations

    • Celladon Corporation, La Jolla, California
    • ,
  • Roger J. Hajjar, MD

      Affiliations

    • Mount Sinai School of Medicine, New York, New York
    • ,
  • on Behalf of the Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Trial Investigators.

Received 22 November 2008 ,Revised 26 January 2009 ,Accepted 26 January 2009.

References 

  1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson T, Flegal K, et al. Heart Disease and stroke statistics—2009 update. A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation Epub. 2008 Dec 15;119:e21–e181
  2. Cleland J, Swedberg K, Poole-Wilson P. Successes and failures of current treatment of heart failure. Lancet. 1998;352(Suppl 1):SI19–SI28
  3. Goldstein D, Oz M, Rose E. Implantable left ventricular assist devices. N Engl J Med. 1998;339:1522–1533
  4. Hajjar R, Zsebo K, Deckelbaum L, Thompson C, Rudy J, Yaroshinsky A, et al. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail. 2008;14:355–367
  5. del Monte F, Hajjar RJ, Harding SE. Overwhelming evidence of the beneficial effects of SERCA gene transfer in heart failure. Circ Res. 2001;88:E66–E67
  6. Hajjar R, Schmidt U, Matsui T, Guerrero J, Lee K, Gwathmey J, et al. Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci. 1998;95:5251–5256
  7. Ly H, Kawase Y, Yoneyama R, Hajjar R. Gene therapy in the treatment of heart failure. Physiology. 2007;22:81–96
  8. Hajjar R, Samulski R. Heart failure: a silver bullet to treat heart failure. Gene Ther. 2006;13:997
  9. Periasamy M, Kalyanasundaram A. SERCA2a gene therapy for heart failure: ready for primetime?. Mol Ther. 2008;16:1002–1004
  10. Hasenfuss G, Reinecke H, Studer R, Meyer M, Pieske B, Holtz J, et al. Relation between myocardial function and expression of sarcoplasmic reticulum Ca2+–ATPase in failing and nonfailing human myocardium. Circ Res. 1994;75:434–442
  11. Schwinger R, Bohm M, Schmidt U, Karczewski P, Bavendiek U, Flesch M, et al. Unchanged protein levels of SERCA II and phospholamban but reduced calcium2+ uptake and calcium2+–ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation. 1995;92:3220–3228
  12. Chaudhri BB, del Monte F, Harding SE, Hajjar RJ. Gene transfer in cardiac myocytes. Surg Clin North Am. 2004;84:141–159
  13. Arai M, Alpert NR, MacLennan DH, Barton P, Periasamy M. Alterations in sarcoplasmic reticulum gene expression in human heart failure. A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circ Res. 1993;72:463–469
  14. de la Bastie D, Levitsky D, Rappaport L, Mercadier J, Marotte F, Wisnewsky C, et al. Function of the sarcoplasmic reticulum and expression of its Ca2+–ATPase gene in pressure overload-induced cardiac hypertrophy in the rat. Circ Res. 1990;66:554–564
  15. Gianni D, Chan J, Gwathmey JK, del Monte F, Hajjar RJ. SERCA2a in heart failure: role and therapeutic prospects. J Bioenerg Biomembr. 2005;37:375–380
  16. Terracciano C, Hardy J, Birks E, Khaghani A, Banner N, Yacoub M. Clinical recovery from end-stage heart failure using left-ventricular assist device and pharmacological therapy correlates with increased sarcoplasmic reticulum calcium content but not with regression of cellular hypertrophy. Circulation. 2004;109:2263–2265
  17. Stüdeli R, Jung S, Mohacsi P, Perruchoud S, Castiglioni P, Seiler C, et al. Diastolic dysfunction in human cardiac allografts is associated with reduced SERCA2a gene expression. Am J Transplant. 2006;6:775–782
  18. Kawase Y, Ly H, Prunier F, Lebeche D, Shi Y, Jin H, et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol. 2008;51:1112–1119
  19. del Monte F, Williams E, Lebeche D, Schmidt U, del Monte F, Rosenzweig A, et al Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca2+-ATPase in a rat model of heart failure. Circulation. 2001;104:1424–1429
  20. Sakata S, Lebeche D, Sakata N, Sakata Y, Chemaly E, Liang L, et al. Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins. J Mol Cell Cardiol. 2007;42:852–861
  21. Byrne M, Power J, Preovolos A, Mariani J, Hajjar R, Kaye D. Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther. 2008 Jul 24;Epub ahead of print
  22. Scallan C, Jiang H, Liu T, Patarroyo-White S, Sommer J, Zhou S, et al. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood. 2006;107:1810–1817
  23. Moskalenko M, Chen L, van Roey M, Donahue B, Snyder R, McArthur J, et al. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J Virol. 2000;74:1761–1766
  24. Wobus Ce H-DB, Girod A, Petersen G, Hallek M, Kleinschmidt JA. Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. Blood. 2000;74:9281–9293
  25. De Marco T, Wolfel E, Feldman A, Lowes B, Higginbotham M, Ghali J, et al. Impact of cardiac resynchronization therapy on exercise performance, functional capacity, and quality of life in systolic heart failure with QRS prolongation: COMPANION trial sub-study. J Card Fail. 2008;14:9–18
  26. Wyrwich K, Nienaber N, Tierney W, Wolinsky F. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care. 1999;37:469–478
  27. Wyrwich K, Tierney W, Wolinsky F. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol. 1999;52:861–873
  28. Rector T. Overview of Minnesota Living With Heart Failure® Questionnaire. Available from: http://www.mlhfq.org/
  29. Alla F, Briançon S, Guillemin F, Juillière Y, Mertès P, Villemot J, et al. Self-rating of quality of life provides additional prognostic information in heart failure. Insights into the EPICAL study. Eur J Heart Fail. 2002;4:337–343
  30. Ingle L, Shelton R, Rigby A, Nabb S, Clark A, Cleland J. The reproducibility and sensitivity of the 6-min walk test in elderly patients with chronic heart failure. Eur Heart J. 2005;26:1742–1751
  31. Pereira-Barretto A, Oliveira Junior MTd, Strunz C, Del Carlo C, Scipioni A, Ramires J. Serum NT-proBNP levels are a prognostic predictor in patients with advanced heart failure. Arq Bras Cardiol. 2006;87:174–177
  32. Bruins S, Fokkema M, Römer J, Dejongste M, van der Dijs F, van den Ouweland J, et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem. 2004;50:2052–2058
  33. Clerico A, Carlo Zucchelli G, Pilo A, Passino C, Emdin M. Clinical relevance of biological variation: the lesson of brain natriuretic peptide (BNP) and NT-proBNP assay. Clin Chem Lab Med. 2006;44:366–378
  34. Hartmann F, Packer M, Coats A, Fowler M, Krum H, Mohacsi P, et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation. 2004;110:1780–1786
  35. Drozdz J, Krzemińska-Pakula M, Plewka M, Ciesielczyk M, Kasprzak J. Prognostic value of low-dose dobutamine echocardiography in patients with idiopathic dilated cardiomyopathy. Chest. 2002;121:1216–1222
  36. Grayburn P, Appleton C, DeMaria A, Greenberg B, Lowes B, Oh J, et al. Echocardiographic predictors of morbidity and mortality in patients with advanced heart failure. J Am Coll Cardiol. 2005;45:1064–1071
  37. Abraham W, Fisher W, Smith A, Delurgio D, Leon A, Loh E, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845–1853
  38. European Medicines Agency. Expert Committee on Medicinal Products Gene Therapy. Report from the CPMP Gene Therapy Expert Group Meeting 26th-27th February 2004, EMEA/CPMP/1879/04/Final. Available at: http://www.emea.europa.eu/pdfs/human/genetherapy/187904en.pdf. Accessed February 23, 2009.
  39. FDA Guidance for Industry: Gene Therapy Clinical Trials - Observing Participants for Delayed Adverse Events, November 2006. Available at: http://www.fda.gov/cber/gdlns/ctclin.pdf. Accessed February 23, 2009.
  40. Carter B. Adeno-associated virus vectors in clinical trials. Hum Gene Ther. 2005;16:541–550
  41. Carter B, Burstein H, Peluso R. AAV vectors for gene delivery. In:  Templeton N editors. Gene and cell therapy: therapeutic mechanisms and strategies. 2nd ed. New York: Marcel Dekker; 2004;p. 55–101
  42. Schnepp B, Jensen R, Chen C, Johnson P, Clark K. Characterization of adeno-associated virus genomes isolated from human tissues. J Virol. 2005;79:14793–14803
  43. Zaiss A, Liu Q, Bowen G, Wong N, Bartlett J, Muruve D. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol. 2002;76:4580–4590
  44. Sandalon Z, Bruckheimer E, Lustig K, Burstein H. Long-term suppression of experimental arthritis following intramuscular administration of a pseudotyped AAV2/1-TNFR:Fc vector. Mol Ther. 2007;15:264–269
  45. Wang J, Xie J, Lu H, Chen L, Hauck B, Samulski R, et al. Existence of transient functional double-stranded DNA intermediates during recombinant AAV transduction. Proc Natl Acad Sci U S A. 2007;104:13104–13109
  46. Jiang H, Pierce G, Ozelo M, de Paula E, Vargas J, Smith P, et al. Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B.. Mol Ther. 2006;14:452–455
  47. Sasano T, Kikuchi K, McDonald A, Lai S, Donahue J. Targeted high-efficiency, homogeneous myocardial gene transfer. J Mol Cell Cardiol. 2007;42:954–961
  48. Maack C, O'Rourke B. Excitation-contraction coupling and mitochondrial energetics. Basic Res Cardiol. 2007;102:369–392

 Funding for this study was provided by Celladon Corporation, La Jolla, CA. RJH is supported in part by grants from the National Institutes of Health: R01 HL078691, HL080498, HL 78731, HL083156, and a Leducq Transatlantic Network.

 R.J. Hajjar: Celladon Corporation, ownership interest (includes stock and stock options, and rights in patents); D.M. Mancini, Celladon Corporation, consultant/advisory board; B. Greenberg, Celladon Corporation, consultant/advisory board; H. Dittrich, Celladon Corporation, ownership interest (includes stock options), consultant/advisory board; K. Borow, Celladon Corporation, significant, consultant/advisory board; K.M. Zsebo, Celladon Corporation, employment.

PII: S1071-9164(09)00035-9

doi: 10.1016/j.cardfail.2009.01.013

Journal of Cardiac Failure
Volume 15, Issue 3 , Pages 171-181 , April 2009

Article Tools

* Image Usage & Resolution